Avian leukosis viruses and polypeptide display

Abstract

The invention provides methods and materials involved in displaying polypeptide sequences using viruses such as avian leukosis viruses. Specifically, the invention provides nucleic acid molecules, collections of nucleic acid molecules, polypeptides, collections of polypeptides, viruses, and collections of viruses as well as methods for making nucleic acid molecules, collections of nucleic acid molecules, polypeptides, collections of polypeptides, viruses, and collections of viruses. The invention also provides methods for obtaining displayed polypeptide sequences that interact with biological molecules and/or cells as well as methods for identifying biological molecules that interact with displayed polypeptides.

1. A polypeptide comprising the sequence set forth in SEQ ID NO:1 and a first amino acid sequence, wherein said first amino acid sequence is heterologous to naturally occurring avian leukosis virus amino acid sequences, and wherein said first amino acid sequence is attached to the amino-terminal portion of said sequence set forth in SEQ ID NO:1. 
     
     
       2. The polypeptide of  claim 1 , wherein said first amino acid sequence is between five and 500 amino acid residues in length. 
     
     
       3. The polypeptide of  claim 1 , wherein said first amino acid sequence is between ten and 250 amino acid residues in length. 
     
     
       4. The polypeptide of  claim 1 , wherein said first amino acid sequence comprises a sequence from a polypeptide selected from the group consisting of receptors, receptor ligands, immunoglobulins, enzymes, and enzyme substrates. 
     
     
       5. The polypeptide of  claim 1 , wherein said polypeptide forms a covalent attachment with an avian leukosis virus transmembrane glycoprotein when said polypeptide is part of an avian leukosis virus. 
     
     
       6. A plurality of polypeptides, wherein each polypeptide comprises the sequence set forth in SEQ ID NO:1 and a first amino acid sequence, wherein said first amino acid sequence of each polypeptide is heterologous to naturally occurring avian leukosis virus amino acid sequences, and wherein said first amino acid sequence of each polypeptide is attached to the amino-terminal portion of said sequence set forth in SEQ ID NO:1. 
     
     
       7. The plurality of polypeptides of  claim 6 , wherein said first amino acid sequence of each polypeptide is different. 
     
     
       8. The plurality of polypeptides of  claim 6 , wherein each polypeptide forms a covalent attachment with an avian leukosis virus transmembrane glycoprotein when part of an avian leukosis virus. 
     
     
       9. A virus comprising a first polypeptide, wherein said first polypeptide comprises the sequence set forth in SEQ ID NO:1 and a first amino acid sequence, wherein said first amino acid sequence is heterologous to naturally occurring avian leukosis virus amino acid sequences, and wherein said first amino acid sequence is attached to the amino-terminal portion of said sequence set forth in SEQ ID NO:1. 
     
     
       10. The virus of  claim 9 , wherein said virus is a retrovirus. 
     
     
       11. The virus of  claim 9 , wherein said virus is an avian leukosis virus or a murine leukemia virus. 
     
     
       12. The virus of  claim 9 , wherein said first polypeptide forms a covalent attachment with an avian leukosis virus transmembrane glycoprotein when said first polypeptide is part of an avian leukosis virus. 
     
     
       13. The virus of  claim 9 , wherein said virus comprises an avian leukosis virus transmembrane glycoprotein. 
     
     
       14. The virus of  claim 13 , wherein said first polypeptide forms a covalent attachment with said avian leukosis virus transmembrane glycoprotein. 
     
     
       15. The virus of  claim 9 , wherein said virus comprises a nucleic acid molecule comprising a first nucleic acid sequence, wherein said first nucleic acid sequence encodes said first polypeptide. 
     
     
       16. The virus of  claim 15 , wherein said nucleic acid molecule comprises a second nucleic acid sequence, wherein said second nucleic acid sequence is heterologous to naturally occurring avian leukosis viruses. 
     
     
       17. The virus of  claim 16 , wherein said second nucleic acid sequence encodes a second polypeptide. 
     
     
       18. The virus of  claim 17 , wherein said second polypeptide is selected from the group consisting of receptors, receptor ligands, immunoglobulins, enzymes, and enzyme substrates. 
     
     
       19. The virus of  claim 16 , wherein said second nucleic acid sequence is located between said first nucleic acid sequence and a 3′ LTR viral sequence. 
     
     
       20. The virus of  claim 9 , wherein said virus is replication-competent. 
     
     
       21. The virus of  claim 9 , wherein said virus is replication-defective. 
     
     
       22. A plurality of viruses, wherein each virus comprises a first polypeptide, wherein each first polypeptide comprises the sequence set forth in SEQ ID NO:1 and a first amino acid sequence, wherein said first amino acid sequence is heterologous to naturally occurring avian leukosis virus amino acid sequences, and wherein said first amino acid sequence is attached to the amino-terminal portion of said sequence set forth in SEQ ID NO:1. 
     
     
       23. The plurality of viruses of  claim 22 , wherein said first amino acid sequence of each first polypeptide is different. 
     
     
       24. The plurality of viruses of  claim 22 , wherein each virus comprises a nucleic acid molecule comprising a first nucleic acid sequence, wherein said first nucleic acid sequence encodes said first polypeptide. 
     
     
       25. The plurality of viruses of  claim 24 , wherein said nucleic acid molecule of each virus comprises a second nucleic acid sequence. 
     
     
       26. The plurality of viruses of  claim 25 , wherein said second nucleic acid sequence of each virus is different. 
     
     
       27. The plurality of viruses of  claim 25 , wherein said second nucleic acid sequence encodes a second polypeptide. 
     
     
       28. The plurality of viruses of  claim 27 , wherein each virus comprises said second polypeptide. 
     
     
       29. The plurality of viruses of  claim 22 , wherein each virus is replication-competent. 
     
     
       30. The plurality of viruses of  claim 22 , wherein each virus is replication-defective. 
     
     
       31. The plurality of viruses of  claim 22 , wherein said plurality is at least 500.